Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-κB pathway in hepatocellular carcinoma cells

In Vivo

Volumn 26, Issue 4, 2012, Pages 671-682

  Chiang, I Tsang ^a   Liu, Yu Chang ^a   Wang, Wei Hsun ^a,b   Hsu, Fei Ting ^a   Chen, Hong Wen ^c   Lin, Wuu Jyh ^d   Chang, Wen Yi ^a   Hwang, Jeng Jong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Hepatocellular carcinoma; Huh 7 cells; MMP 9; NF B; Sorafenib; VEGF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; SORAFENIB; VASCULOTROPIN;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION;

EID: 84865101209     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Ver.1.2: http://globocan.iarc.fr. Accessed 29th, January, 2012.
2. Poon RT and Fan ST: Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 10 : S39-45, 2004.
3. Comoglio PM and Trusolino L: Invasive growth: from development to metastasis. J Clin Invest 109 : 857-862, 2002.
4. Coussens LM and Werb Z: Matrix metalloproteinases and the development of cancer. Chem Biol 3: 895-904, 1996.
5. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST and Wong J: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20 : 1775-1785, 2002.
6. Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY and Tarnawski AS: Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? Mod Pathol 16: 552-557, 2003.
7. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature 431: 461-466, 2004.
8. El-Serag HB: Hepatocellular Carcinoma. N Engl J Med 365: 1118-1127, 2011.
9. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441 : 431-436, 2006.
10. Luedde T and Schwabe RF: NF-kappaB in the liver - linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8 : 108-118, 2011.
11. Maeda S, Kamata H, Luo JL, Leffert H and Karin M: IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121: 977-990, 2005.
12. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H and Maluccio MA: NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett 278: 145-155, 2009.
13. Hah N and Lee ST: An absolute role of the PKC-dependent NFkappaB activation for induction of MMP-9 in hepatocellular carcinoma cells. Biochem Biophys Res Commun 305: 428-433, 2003.
14. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
15. Schomer-Miller B, Higashimoto T, Lee YK and Zandi E: Regulation of IkappaB kinase (IKK) complex by IKKgammadependent phosphorylation of the T-loop and C terminus of IKKbeta. J Biol Chem 281: 15268-15276, 2006.
16. Liu YC, Chiang IT, Hsu FT and Hwang JJ: Using NF-κB as a molecular target for theranostics in radiation oncology research. Expert Rev Mol Diagn 12 : 139-146, 2012.
17. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous activation of RAS and JAK/STAT pathways in human HCC. Gastroenterology 130: 1117-1128, 2006.
18. Siegel AB, Olsen SK, Magun A and Brown RS Jr.: Sorafenib: Where do we go from here? Hepatology 52: 360-369, 2010.
19. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G and Trail PA: BAY 43-9006 exhibits broadspectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 : 7099-7109, 2004.
20. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006.
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. New Engl J M 359 : 378-390, 2008.
22. Arsura M, Mercurio F, Oliver AL, Thorgeirsson SS and Sonenshein GE: Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol 20: 5381-5391, 2000.
23. Lin CW, Shen SC, Chien CC, Yang LY, Shia LT and Chen YC: 12-O-Tetradecanoylphorbol-13-acetate-induced invasion/migration of glioblastoma cells through activating PKCalpha/ERK/NF-kappaB- dependent MMP-9 expression. J Cell Physiol 225: 472- 481, 2010.
24. Kim S, Choi JH, Lim HI, Lee SK, Kim WW, Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ and Lee JE: Silibinin prevents TPAinduced MMP-9 expression and VEGF secretion by inactivation of the RAF/MEK/ERK pathway in MCF-7 human breast cancer cells. Phytomedicine 16: 573-580, 2009.
25. Zhou X, Yang J, Wang Y, Li W, Li-Ling J, Deng Y and Zhang M: Cucurbitacin B inhibits 12 - O-tetradecanoylphorbol-13-acetateinduced invasion and migration of human hepatoma cells through inactivating mitogen-activated protein kinase and PI3K/AKT signal transduction pathways. Hepatol Res 42: 401-411, 2012.
26. Kuo YC, Lin WC, Chiang IT, Chang YF, Chen CW, Su SH, Chen CL and Hwang JJ: Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo. Biomed Pharmacother 66 : 12-20, 2012.
27. Bankston D, Dumas J, Natero R, Riedl B, Monahan M and Sibley R: A scaleable synthesis of BAY 43-9006: A potent RAF kinase inhibitor for the treatment of cancer. Org Process Res Dev 6: 777-781, 2002.
28. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr., Sledge GW Jr. and Nakshatri H: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19: 4159-4169, 2000.
29. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 1155: 206-221, 2009.
30. Wiedmann MW and Mossner J: Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies. Curr Cancer Drug Targets 11: 714-733, 2011.
31. Mayoral R, Fernandez-Martinez A, Bosca L and Martin-Sanz P: Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 26: 753-761, 2005.
32. Lee YR, Noh EM, Oh HJ, Hur H, Kim JM, Han JH, Hwang JK, Park BH, Park JW, Youn HJ, Jung SH, Kim BS, Jung JY, Lee SH, Park CS and Kim JS: Dihydroavenanthramide D inhibits human breast cancer cell invasion through suppression of MMP-9 expression. Biochem Biophys Res Commun 405 : 552-557, 2011.
33. Ruhul Amin AR, Senga T, Oo ML, Thant AA and Hamaguchi M: Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1beta: a role for the dual signalling pathways, AKT and ERK. Genes Cells 8: 515-523, 2003.
34. Feng YX, Wang T, Deng YZ, Yang P, Li JJ, Guan DX, Yao F, Zhu YQ, Qin Y, Wang H, Li N, Wu MC, Wang HY, Wang XF, Cheng SQ and Xie D: Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53: 483-492, 2011.
35. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD and El- Deiry WS: Reduction of TRAIL-induced MCL-1 and cIAP2 by c-MYC or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12: 66-80, 2007.
36. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Buchler MW, Zoller M, Salnikov AV and Herr I: Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70 : 5004-5013, 2010.